Peptidyl-tRNA hydrolase (Pth) cleaves the ester bond between the peptide and the tRNA of peptidyl-tRNA molecules, which are the product of aborted translation. In the present work, Pth from Escherichia coli was crystallized with the acceptor-TÉC domain of tRNA using 1,4-butanediol as a precipitant. The crystals belonged to the hexagonal space group P6 1 , with unit-cell parameters a = b = 55.1, c = 413.1 Å , and diffracted X-rays beyond 2.4 Å resolution. The asymmetric unit is expected to contain two complexes of Pth and the acceptor-TÉC domain of tRNA (V M = 2.8 Å 3 Da À1 ), with a solvent content of 60.8%. The structure is being solved by molecular replacement.
Introduction
During the course of protein synthesis, peptidyl-tRNA is prematurely produced from the ribosome as a result of aborted translation (Menninger, 1976) . The accumulation of peptidyl-tRNA limits the amount of free tRNA for protein synthesis; therefore, such an accumulation is toxic to cells (Atherly, 1978; Menninger, 1979) . This situation is prevented by the activity of peptidyl-tRNA hydrolase (Pth), which releases tRNA from peptidyl-tRNA by cleaving the ester bond between the C-terminal end of the peptide and the 2 0 -or 3 0 -hydroxyl of the ribose at the 3 0 end of the tRNA (Cuzin et al., 1967; Kö ssel & RajBhandary, 1968; Das & Varshney, 2006) . Pth is ubiquitous in nature and can be classified into two types: Pth, which is sometimes referred to as Pth1, and Pth2. Pth exists in bacteria and eukaryotes (Kö ssel, 1970; Brun et al., 1971; Menez et al., 2002) , whereas Pth2 is present in eukaryotes and archaea (Rosas-Sandoval et al., 2002; Fromant et al., 2003) . Despite a lack of sequence similarity, the two enzyme classes have similar biological activities. Indeed, Escherichia coli strains lacking endogenous Pth are rescued by the expression of Pth2 (Rosas-Sandoval et al., 2002; Fromant et al., 2003) . The activity of Pth is known to be essential for the viability of bacteria (Atherly & Menninger, 1972; Menez et al., 2002) .
The biochemical features of E. coli Pth have been well studied. N-blocked aminoacyl-tRNAs are the shortest substrates of the enzyme (Cuzin et al., 1967; Kö ssel & RajBhandary, 1968) ; however, N-formylmethionyl-tRNA f Met is resistant to attack by Pth (Kö ssel & RajBhandary, 1968; Kö ssel, 1970) . Indeed, formylated initiator tRNA must be kept intact in order to participate in the formation of the ribosomal initiator complex. This resistance is thought to be a consequence of the lack of base pairing at position 1-72 in tRNA f Met , which may cause incorrect positioning of the 5 0 -phospate that is necessary for Pth activity (Schulman & Pelka, 1975; Dutka et al., 1993) . However, the molecular mechanism of this substrate discrimination remains unknown. In contrast, Pth can accept many kinds of peptidyl or N-blocked aminoacyl-elongator tRNAs (Kö ssel & RajBhandary, 1968; de Groot et al., 1969) . The enzyme recognizes both the peptidic and the nucleotidic moieties of the substrate (Shiloach et al., 1975) , both of which consist of various sequences depending on the substrate. The mechanism for this broad substrate specificity also remains unknown.
The structures of Pth from E. coli , Mycobacterium tuberculosis (Selvaraj et al., 2007; Pulavarti et al., 2008) and Francisella tularensis (Clarke et al., 2011) have been determined. Structures of Pth2 from Homo sapiens (de Pereda et al., 2004) , Sulfolobus solfataricus (Fromant et al., 2005) , Archaeoglobus fulgidis (Powers et al., 2005) and Pyrococcus horikoshii (Shimizu et al., 2008) have also been reported. In combination with biochemical experiments, these structural studies have enabled us to predict the catalytic residues and substrate-recognition regions of the enzymes. Because all of these structures have been determined in the apo form, however, the molecular mechanism of the reaction remains unclear. Thus, as a first step towards elucidating this mechanism, we attempted to crystallize E. coli Pth with full-length tRNA, a competitive inhibitor of Pth (Shiloach et al., 1975) . In addition, we attempted to crystallize E. coli Pth with the acceptor-TÉC domain of tRNA, because the enzyme has been predicted to bind to the tRNA moiety of the substrate through this region (Fromant et al., 1999) and this region is thought to be structurally stable. Here, we report sample preparation, crystallization and preliminary X-ray crystallographic analysis. This is the first report of the crystallization of Pth in complex with its ligand.
Materials and methods

Preparation of full-length tRNA
The pET vector containing the full-length mature E. coli tRNA Ala GGC sequence was a gift from Dr Takashi Yokogawa (Gifu University, Japan). A template for in vitro transcription was obtained by PCR with the above vector and the following pair of oligo DNAs: 5 0 -GAAATTAATACGACTCACTATAGGGGCTATAGCTCAGCT-GGGA-3 0 and 5 0 -TmGGTGGAGCTAAGCGGGATCG-3 0 . The T7 RNA polymerase promoter sequence is represented in bold. mG represents the 2 0 -O-methyl nucleotide, which is used to manipulate the uniform 3 0 ends of transcribed products (Sherlin et al., 2001) . To obtain tRNA bearing a monophosphorylated guanosine at the 5 0 terminus, the RNA was synthesized by in vitro transcription using T7 RNA polymerase in the presence of a tenfold molar excess of GMP over GTP. The transcribed product was purified by phenol/chloroform treatment. The product was dialyzed against buffer consisting of 20 mM HEPES-KOH pH 7.6, 200 mM KCl. For renaturation, the solution was heated at 343 K for 5 min, followed by the addition of MgCl 2 to 10 mM and gradual cooling to 298 K. The sample was further purified on a HiTrap Q HP column (GE Healthcare), using 20 mM HEPES-KOH pH 7.6 containing 150 mM KCl as a starting buffer, with a linear gradient of 150-1000 mM KCl. Finally, the RNA was exchanged to buffer A (10 mM HEPES-KOH pH 7.6 containing 10 mM MgCl 2 and 7 mM -mercaptoethanol) and concentrated using a Vivaspin centrifugal concentrator (3 kDa cutoff; Sartorius). The sample was stored at 193 K prior to use.
Preparation of the acceptor-TWC domain of tRNA
The DNA fragment encoding the acceptor-TÉC domain of the E. coli tRNA Ala GGC gene, with the preceding sequence of the T7 RNA polymerase promoter (GAAATTAATACGACTCACTATAGGG-GCTAAGCGGTTCGATCCCGCTTAGCTCCACCA, in which the T7 RNA polymerase promoter sequence is represented in bold), was PCR-amplified and cloned into the pUC18 vector. A template for in vitro transcription was obtained by PCR with the above vector and the following pairs of oligo DNAs: 5 0 -GAAATTAATACGA-CTCACTATAG-3 0 and 5 0 -TmGGTGGAGCTAAGCGGGATCG-3 0 . mG represents the 2 0 -O-methyl nucleotide, which is used for manipulating the uniform 3 0 end of transcribed products (Sherlin et al., 2001) . In vitro transcription and purification were performed in a manner similar to that for full-length tRNA.
Overexpression and purification of E. coli Pth
A method for the purification of E. coli Pth has been reported previously (Dutka et al., 1993; ; however, we purified this enzyme more easily and effectively with a His tag as follows. The gene encoding E. coli Pth was PCR-amplified and cloned into the pET-15b vector (Novagen). The recombinant protein was overexpressed in E. coli strain BL21 (DE3) (Novagen) with an N-terminal His tag and a thrombin cleavage site (MGSSHHHHH-HSSGLVPR/GSH, where / represents the thrombin cleavage site). After sonication of E. coli cells in buffer B (50 mM HEPES-KOH pH 7.6 containing 1 M ammonium chloride and 7 mM -mercaptoethanol), the clarified lysate was loaded onto a HisTrap HP column (GE Healthcare) equilibrated with buffer B. His-tagged Pth was eluted with a linear gradient to 50 mM HEPES-KOH buffer pH 7.6 containing 100 mM KCl, 7 mM -mercaptoethanol and 200 mM imidazole. The His-tagged Pth was then cleaved by the addition of thrombin. The protease was inactivated and removed by adding Benzamidine Sepharose 4 Fast Flow (high sub; GE Healthcare), followed by filtration. To remove isolated His tag and undigested Histagged Pth from untagged Pth, the protein solution was diluted four times with buffer B and loaded onto an Ni-NTA agarose (Qiagen) column equilibrated with buffer B. The flowthrough fraction was then collected and dialyzed against buffer C (10 mM HEPES-KOH pH 7.6 containing 7 mM -mercaptoethanol). Subsequently, to absorb residual contaminant proteins, the flowthrough fraction of the Ni-NTA agarose column was loaded onto a Q Sepharose Fast Flow (GE Healthcare) column equilibrated with buffer C. The flowthrough fraction was collected and concentrated using an Amicon Ultra centrifugal concentrator (10 kDa cutoff, Millipore). The sample was stored at 193 K prior to use.
Crystallization and X-ray data collection
Initial crystallization trials were performed by the sitting-drop vapour-diffusion method using Crystal Screen, Crystal Screen 2, Crystal Screen Lite, Natrix (Hampton Research) and Wizard I and II (Emerald BioSystems). Pth and full-length tRNA or the acceptor-TÉC domain of tRNA were mixed in buffer A in a 1:2 molar ratio with a final Pth concentration of 7 mg ml À1 . The mixture was heated at 310 K for 10 min and gradually cooled to 298 K. Sitting drops were prepared by mixing 1 ml sample solution with an equal volume of reservoir solution and were equilibrated against 50 ml reservoir solution in a 96-well plate at 293 K. Trials to improve the crystallization conditions were performed by varying the pH, temperature, precipitant concentration, protein concentration, molar ratio of protein to RNA and sample and reservoir solution volumes, as well as by the use of Additive Screen (Hampton Research). All of these trials were performed by the sitting-drop vapour-diffusion method using 24-well plates and the drops were equilibrated against 450 ml reservoir solution.
For data collection under cryogenic conditions, crystals were mounted in nylon loops (Hampton Research), transferred into a reservoir solution containing ethylene glycol and flash-cooled in a stream of nitrogen. X-ray diffraction data were collected at 100 K on the BL41XU beamline at SPring-8 (Harima, Japan) using a MAR 225 crystallization communications CCD detector. Diffraction data were processed and scaled using XDS (Kabsch, 2010) ; other crystallographic calculations were carried out with the CCP4 package (Winn et al., 2011) .
Results and discussion
Pth was overexpressed and purified with a yield of 110 mg protein from 1 l culture. The purity of the protein was estimated to be greater than 95% by SDS-PAGE. Full-length tRNA and the acceptor-TÉC domain of tRNA were synthesized by in vitro transcription with T7 RNA polymerase. The purity of the RNA was estimated to be greater than 90% by urea PAGE.
We could not obtain crystals of Pth in complex with full-length tRNA from the initial crystallization trials. We think that flexible structural features of the tRNA might cause problems in crystallization. In contrast, microcrystals of less than 10 mm were obtained with Wizard I condition No. 35 [100 mM acetate buffer pH 4.5, 20%(w/v) 1,4-butanediol] in the case of initial crystallization trials with the acceptor-TÉC domain of tRNA, which is thought to be structurally more stable than full-length tRNA. No other crystallization conditions were found in the initial trials. As a result of refining these crystallization conditions, crystals suitable for X-ray analysis were obtained by the sitting-drop vapour-diffusion method by mixing 1 ml sample solution (with a 1:2.5 molar ratio of Pth to the acceptor-TÉC domain of tRNA and a final Pth concentration of 14 mg ml À1 ) and 1 ml reservoir solution consisting of 100 mM acetate buffer pH 5.2, 20%(w/v) 1,4-butanediol and 30 mM glycyl-glycylglycine. The crystals grew within two weeks to maximum dimensions of 100 Â 100 Â 30 mm at 293 K (Fig. 1) . No crystals were obtained when a sample solution containing only protein or RNA was used, suggesting that the crystals contained both Pth and the acceptor-TÉC domain of tRNA. We will provide further evidence that the crystals contain both Pth and the acceptor-TÉC domain of tRNA. It is interesting that glycyl-glycyl-glycine significantly improved the size of the crystals, as a peptide is a product of the Pth reaction. Binding of glycyl-glycyl-glycine to the active site may influence the conformation of the enzyme and the crystal packing.
Diffraction data were collected from a cryocooled crystal using a MAR 225 CCD detector on BL41XU at SPring-8. Ice-ring formation was prevented by using reservoir solution containing 10%(v/v) ethylene glycol. The wavelength was set to 1.000 Å , the oscillation angle was set to 0.4 and the crystal-to-detector distance was set to 270 mm. The crystals diffracted X-rays to beyond 2.4 Å resolution (Fig. 2) . Analysis of merging statistics and systematic absences indicated that the crystals belonged to the hexagonal space group P6 1 or P6 5 , with unit-cell parameters a = b = 55.1, c = 413.1 Å . Under the assumption that the crystals were a complex of Pth and the acceptor-TÉC domain of tRNA, the crystals were expected to contain two complexes per asymmetric unit, corresponding to a solvent content of 60.8% and a Matthews coefficient V M (Matthews, 1968 ) of 2.8 Å 3 Da À1 (the molecular weight of Pth is 21.1 kDa and that of the acceptor-TÉC domain of tRNA is 11.2 kDa). Indeed, these crystals included both components (see below). The data-collection statistics are summarized in Table 1 .
In order to solve the structure, molecular replacement with MOLREP (Vagin & Teplyakov, 2010) was attempted using the structure of E. coli Pth (PDB code 2pth; ) as a search model, which produced a clear solution. The space group was determined to be P6 1 . The electron density of the acceptor-TÉC domain of tRNA was then obtained by phase improvement with ARP/wARP (Perrakis et al., 1999) and initial model building of the acceptor-TÉC domain of tRNA was able to proceed automatically with PHENIX (Adams et al., 2002;  Fig. 3 ). These results showed that the crystals obtained were a complex of Pth and the acceptor-TÉC domain of tRNA. Structure refinement is now in progress.
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Figure 3
A -weighted 2F o À F c electron-density map surrounding part of the acceptor-TÉC domain of tRNA. The map is contoured at 1.5. The molecule is shown as a stick model, with C atoms in grey, O atoms in red, N atoms in blue and P atoms in orange. The figure was prepared with PyMOL (DeLano, 2002).
